Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution
Travoprost 0.004% Eye · 1 trial · 2 indications
For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis
For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis
For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis
| Arm | Type | Description |
|---|---|---|
| TRAVATAN APS | EXPERIMENTAL | One drop once daily in the evening for 3 months |
| TRAVATAN | ACTIVE_COMPARATOR | One drop once daily in the evening for 3 months |
| Name | Type | Description |
|---|---|---|
| Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution | DRUG | One drop once daily in the evening for 3 months |
| Travoprost 0.004% (BAK-preserved) Eye Drops, Solution | DRUG | One drop once daily in the evening for 3 months |
Inclusion Criteria: * 18 years of age or older, either gender and any race. * Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT). * Not currently on any IOP-lowering medication or currently on a stable treatment (i.e, at least 30 days) with and IOP-lowering monotherapy. * All patients: Mean IOP...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |